Immunoglobulin Potency and Purity Considerations for Patients With Primary Immunodeficiency

INTRODUCTION AND BACKGROUND

Primary immunodeficiency (PID) diseases occur in about 1 in every 1200 individuals and are associated with recurrent infections and several comorbidities that contribute to its substantial morbidity and mortality, especially prior to diagnosis.1-5 Most PID diseases are chronic, and, thereby require continuous treatment.2,6 Herein, the epidemiology, clinical burden, and economic burden of PID will be summarized. Additionally, current treatment options for PID will be reviewed and a subcutaneous (SC) immunoglobulin G (IgG) therapy will be introduced.

Disease Overview

PID diseases are a group of chronic, noncontagious disorders that are characterized by a dysregulated immune system. PID is caused by genetic or hereditary defects and affects both children and adults. There are over 400 rare types of PID disorders that can affect 1 or more components of the immune system.7 They can be categorized based on whether they affect specific or adaptive immunity (eg, humoral or antibody deficiencies) or combined deficiencies affecting both humoral and cellular immune mechanisms.8 Approximately half of all patients with a diagnosis of PID have antibody deficiencies.3

Patients with PID have variable clinical presentations of the disease, although most have higher predisposition to infections.9 These infections are periodic or due to unusual organisms and can affect the skin, ears, brain, spinal cord, respiratory system, urinary tract, or gastrointestinal tract.2 The affected organ systems and pathogens involved vary based on the type of immune defect, although many immunodeficiencies have autoimmune disease and malignancy characteristics as a common phenotype.8

Diagnosis of PID typically does not occur until after a patient experiences recurrent or severe infections, highlighting the need for earlier detection.2 The average time to diagnosis of PID after onset of symptoms is 12.4 years, and in some patients it may take up to 20 years for a diagnosis.10,11 A delayed diagnosis of PID can result in permanent functional impairment, loss of function, and substantial morbidity. In a 2013 survey of 1394 patients with PID conducted by the Immune Deficiency Foundation (IDF), patients reported permanent impairment or losses in lung function (28%), hearing (15%), digestive function (14%), mobility (9%), neurological function (9%), vision (6%), kidney function (3%), and liver function (2%) prior to PID diagnosis.10 In separate analyses, a delayed diagnosis of PID was most commonly associated with recurrent sinusitis, recurrent pneumonia, and/or subsequent treatment with IgG.3,5 PID diagnosis may be suspected if there are recurrent or persistent infections, when mild childhood disease becomes life-threatening, or if there are high or low blood cell counts.2 PID is most often diagnosed by an immunologist and 17% of patients have a family history.11

Epidemiology

PID is estimated to occur in 83.3 per 100,000 individuals based on a 2007 survey sample of 10,000 households.1 This estimate corresponds to an estimated prevalence of 270,193 of 3.13 million in the United States, based on an estimation of the 2011 US population drawn from World Population Prospects, 2010 Revision.1,12 Results of several studies have demonstrated PID prevalence has increased over time in the United States.13,14 In 1 report, the prevalence of diagnosed PID increased by 30% and 41% from 2001 to 2007 and 2001 to 2005, respectively.13 The physician-reported prevalence of patients with PID increased by 57% from 2013 to 2018 (40,560 patients in 2013 and 63,684 patients in 2018).14 Campaigns to educate and raise awareness of PID among health care providers and the general public may have contributed to the rise in incidence and prevalence of PID over time.13

Clinical Burden of PID

PID is associated with substantial morbidity and mortality in a majority of patients, especially due to increased susceptibility to infections.4,13 Additional comorbidities in patients with PID include gastrointestinal diseases, liver diseases, autoimmune diseases, cytopenias, and cancer.3,15 To understand the burden of PID-associated morbidity, the number of hospital admissions and length of hospitalizations for patients with PID were identified using claims data from the Truven Health MarketScan of Commercial Claims and Encounters (from 2001-2007) and Multi-State Medicaid databases (from 2001-2005). Patients with PID were 2 times more likely to be hospitalized and have significantly longer hospital stays than patients without PID, which may partly be due to infections and other comorbidities.13 According to data from the National Center for Health Statistics from 1999 to 2014, the overall age-adjusted mortality rate in patients with PID was 0.43 per 1,000,000 population (95% CI, 0.40-0.46), with the highest mortality rates from the southern part of the United States (36% PID-related deaths).4 The contributing cause of mortality in the US PID population included extrapulmonary infections (35%), respiratory illnesses that were either infectious (eg, pneumonia) or noninfectious (eg, acute respiratory distress syndrome) pulmonary illnesses (17%), cardiovascular (11%), endocrine/metabolic (6%), and malignancy (5%).4 Some serious complications of primary antibody deficiency may be fatal. Patients with PID have a 10-year survival rate of 93.5% after diagnosis with PID.3,15,16

The results of studies have reported that patients with PID experience lower health-related quality of life (HRQOL) than those without PID.17,18 In a 2016 observational study of 18 adult patients and 8 pediatric patients diagnosed with PID—specifically primary antibody deficiencies—HRQOL was assessed through self-administered questionnaires.17 Patients who were eligible were recently diagnosed with or suspected of having common variable immunodeficiency, X-linked agammaglobulinemia, or autosomal recessive agammaglobulinemia, or specific antibody deficiency. Patients who had a life expectancy of 1 year or less, dementia and/or mental incapacity, or comorbidities or other conditions that would interfere with interpretation of the data were excluded. The 36-question Short Form Health Survey, version 2 (SF-36v2) was used to assess HRQOL in adults; it measures 8 domains including limitations in physical activities because of health problems (physical function), limitations in usual role activities because of physical health problems (role physical), bodily pain, general health perceptions, mental component score, vitality (ie, energy and fatigue), limitations in social activities because of physical or emotional problems (social functioning), limitations in usual role activities because of emotional problems (role emotional), general mental health (ie, psychologic distress and well-being). The Pediatric Quality of Life Inventory was used in children, which evaluates physical, emotional, social, and school-related parameters. Comparative samples were age- and sex-matched using separate least squares multiple regression models for each QOL scale and summary measure with the available normative data for the SF-36v2. For the mental health domains of the SF-36v2, adult patients with PID experienced significantly diminished (P <.05) vitality (38.2 vs 49.4), social functioning (33.6 vs 49.8), and role emotional (41.0 vs 49.7), but not mental health, compared with the general US population. Compared with the general US population, adult patients with PID had lower HRQOL scores, with significantly lower scores on the physical domains assessed by the SF-36v2. (Table 1). In children, The Pediatric Quality of Life Inventory, which evaluates physical, emotional, social, and school-related parameters was used. Some pediatric patients reported an improvement after 12 months of treatment, however, others reported no change or worsening of their HRQOL; changes were not significant.17

In a separate survey-based 2-part study, 945 adult patients with common variable immune deficiency completed a 75-question survey (IDF survey), followed by a 12-question Short Form Health Survey (SF-12), to assess their HRQOL as a measure of disease burden. Results of the survey showed that the population with PID reported substantially diminished functional health and well-being compared with the general US population.18

Economic Burden of PID

Prior to diagnosis of PID, patients experience a substantially higher rate of acute infections (6.38 vs 1.78), severe infections (4.32 vs 0.59), and bacterial pneumonias (2.84 vs 0.62) compared with postdiagnosis (Table 2).19 As a result of this increased infection burden in patients with PID who have not yet been diagnosed, there is potential that greater healthcare resource utilization for infection management and productivity losses may drive the economic burden of this disease even before diagnosis. For example, this increased rate of infection can lead to more days in the hospital (70.88 vs 11.79) and a greater number of school or work days missed (33.90 vs 8.90) compared with patients who experience infections postdiagnosis.19 The estimated annual cost of PID per patient prior to diagnosis was $138,760.19 After diagnosis and IgG replacement therapy, including the cost of treatment, the estimated cost per patient was $60,297—an annual savings of $78,166 that is attributable to treatment of PID.17,19 A report conducted in 2018 found that the annual savings post diagnosis were $85,882 globally.14

In patients treated with IgG therapy, infections are common, with 2.16 infections per patient per year on average.20 A retrospective claims analysis investigated the cost of infection among patients with PID, including infection-related resource utilization and infection-related medical expenditures longitudinally across a 7-month period.21 A total of 1742 patients with a diagnosis of PID and healthcare claims for immunoglobulin intravenous (IGIV) therapy were identified from the Truven Health Analytics MarketScan Commercial Research Database (January 1, 2008, to September 30, 2010).21 Across the 7-month study period, 490 patients had claims for a resource that indicated they experienced 1 or more infections; of those patients, 89.8% had 1 or more infection-related office visits and 25.1% had infection-related inpatient hospitalizations.21 The mean total infection-related medical expenses were $11,925 per patient during the 7-month study period.21 Among the drivers of infection-related resource utilization, inpatient hospitalizations, outpatient visits, and emergency department visits were the highest cost contributors per patient ($38,574, $1460, and $899, respectively).21

CURRENT TREATMENT OPTIONS AND UNMET NEEDS

IgG, the Main Treatment Modality for PID

Treatment of PID antibody deficiency using IgG replacement therapy is common for most patients (administered through IV or SC).2 Patients with selective immunoglobulin A (IgA) deficiency and transient hypogammaglobulinemia of infancy are typically not treated with IgG replacement therapy.2 IgG replacement therapy contains purified pooled plasma with a broad spectrum of antibodies from multiple individuals (10,000-50,000).6 It is a lifelong therapy that requires repeat doses of IgG at regular intervals because the body produces IgG from its own immune cells and IgG must be replenished periodically.6 The typical half-life of IgG antibodies is about 19 to 21 days.2 IGIV is administered every 3 or 4 weeks, whereas IGSC may be administered daily, weekly, or every 3 to 4 weeks depending on the specific IGSC product administered.6 The dominant route of administration for IgG therapy has historically been IV22; however, more recent data show SC infusion to be an acceptable form of therapy for patients with PID.23 The use of IGSC has increased from 23.0% in 2008 to 45.2% in 2013 based on IDF surveys conducted during that time.10,24 Additionally, of 509 patients who switched from IGIV to IGSC, 55% of those patients reported they made the decision due to the convenience of IGSC therapy.10

IgG replacement therapy has resulted in improved in HRQOL in patients with PID administered through IV and SC.17 A 12-month observational study assessed the burden of disease of PID along with impact of IgG treatment on HRQOL as measured by the SF-36v2.17 Patients with PID experienced significant improvements in SF-36v2 domain score including physical role (34.7 vs 43.5; P = .01), general health (31.2 vs 40.3; P = .02), and social functioning (36.1 vs 44.9; P = .02) from baseline to 12 months of IgG treatment, respectively.17

Unmet Needs and Considerations in IgG Treatment

SC administration of IgG preparations provides another option for patients with poor venous access and a history of adverse events (AEs) to IGIV, and offers patient convenience due to at-home administration and lower infusion volume requirements.25 In a 2008 survey conducted among patients with PID (N = 68), 8% reported discontinuation of IgG therapy due to safety issues or AEs.24 AEs that occurred in 10% or more of the population treated with IGIV-10% included headaches, muscle aches, abdominal pain, fever/chills, an increase or decrease in blood pressure, anxiety, redness or swelling at infusion site, and wheezing (Table 3).24 In contrast, fewer systemic AEs are associated with IGSC and the majority are infusion site reactions.6 The results of another study found that more IGIV-treated patients reported experiencing fatigue and with greater frequency than IGSC-treated patients (46.0% vs 28.5%, respectively).18 Among the IGIV products available, there are numerous differences in product-specific formulations and features, including clinical tolerability, volume load, osmolality, sodium content, sugar content, pH, and IgA content.24,25 Formulas with a higher IgG concentration require lower volume and shorter infusion time. A greater incidence of thromboembolic complications is associated with formulations with higher sodium, whereas renal failure or insufficiency is associated with higher sugar content.26

An additional consideration with IGIV treatment is the wear-off effect that can occur toward the end of the dosing cycle. Three phase 3 studies were included in a pooled analysis of patients treated with IGIV for 3 or 4 weeks. The probability of acquiring an infection significantly increased during the final cycle week—by 1.26 and 1.55 for patients on 3- and 4-week dosing schedules, respectively—compared with week 1, suggesting a wear-off effect of the drug.27 Further, IgG replacement therapy only replaces circulating IgG levels and not external secretions of IgG, a factor that must be considered because infections that involve mucosal surfaces can be an issue.2

IGSC administration occurs at home, either via self-infusion or with the help of a caregiver, resulting in improvements in HRQOL and patient satisfaction versus administration of IGIV at a physician’s office or a hospital.23,28 Patients who received home infusions had higher HRQOL scores compared with patients who received treatment at an infusion suite.18 Additionally, adults and children with PID who switched from IGIV to IGSC had improved perceptions of general health after 12 months of treatment.29 Rider et al compared HRQOL in number of patients by route of IgG administration. In patients who perceived their PID to be less than adequately controlled, their mental component score of the SF-12 was higher when treated with IGSC compared with IGIV.18

The measurement of serum trough IgG levels to ensure adequate protection against infection is important when administering IgG therapy.6 A meta-analysis of pneumonia rates and trough IgG levels showed that with every 100 mg/dL increment in trough IgG the rate of pneumonia incidence declined by 27%.30 A clinical study measured serum trough IgG levels in patients (n = 51) during IGSC treatment and compared them with levels that were previously recorded while the patients had IGIV therapy. Mean serum trough IgG levels with IGSC were 25% to 34% higher than the recorded levels for each subject during IGIV treatment.29 Therefore, serum trough IgG levels should be checked more often when a patient first starts IgG replacement therapy and then once per year after commencing therapy to determine if there are differences in the metabolism of blood levels of IgG.2

IGSC-C 20% FOR PID

Product Description

The FDA approved Xembify® (immune globulin subcutaneous, human—klhw) a 20% immune globulin solution for SC infusion (referred to as IGSC-C 20%) in July 2019.28,31 It is indicated as a weekly SC dose for the treatment of primary humoral immunodeficiency in patients at least 2 years old. If desired, the dose may be divided into 2 to 7 infusions per week. It provides a wide spectrum of opsonizing and neutralizing IgG antibodies that fight bacterial, viral, parasitic, and mycoplasma agents and their toxins as well as antibodies able to interact and alter immune cell activity.28 The product is an appropriate option for patients with risk factors, including pediatric and elderly patients, and patients with diabetes, renal dysfunction, thromboembolic risk, and/or cardiac impairment.26 It has trace amounts of sodium, is sugar-free, and is close to physiologic osmolality.25,26 This is achieved through a unique manufacturing process using caprylate/chromatography. Caprylate is a safe, naturally occurring fatty acid of plant origin that is used in both the purification and virus-inactivation capacity steps of the manufacturing process. This process provides at least 98% IgG protein for maximum potency and maximum purity. Caprylate/chromatography yields maximum amounts of IgG protein, maintains IgG in liquid phase, and minimizes the denaturing of the IgG protein. The final result is a ready-to-use, sterile SC infusion that can be administered at home.28

IGSC-C 20% is manufactured by Grifols, similar to IGIV-C 10%, through a combination of cold ethanol fractionation, caprylate precipitation and filtration, and anion-exchange chromatography of plasma pooled from healthy human donors.25,32 Although the plasma fractionation and caprylate purification steps are the same for IGIV-C 10% and IGSC-C 20%, there are additional steps required to refine the formulation into an IGSC-C 20%, resulting in an approximately 55% increase in manhours and production equipment time compared with that of IGIV-C 10%. The IGSC-C 20% production involves a second purification and sterilization. IGSC-C 20% was found to have a similar composition, antibody potency, and purity as IGIV-C 10%, but it utilizes a smaller volume for administration than IGIV-C 10%, which results in shorter infusion times.25,26 The antibody potencies of IGSC-C 20% and IGIV-C 10% were tested for diphtheria, measles, polio, hepatitis A, hepatitis B, and parvovirus and were found to be comparable and above the US minimum requirements. In 2018, the FDA lowered the specification for measles (from 0.48 × reference to 0.36 × reference), but IGSC-C 20% still maintains the higher specification previously required.25

INDICATION

XEMBIFY® (immune globulin subcutaneous human—klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. XEMBIFY is for subcutaneous administration only.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS

  • Thrombosis may occur with immune globulin products, including XEMBIFY. Risk factors may include: advanced age, prolonged immobilization, estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • For patients at risk of thrombosis, administer XEMBIFY at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity

Contraindications

XEMBIFY is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. It is contraindicated in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.

Warnings and PrecautionsHypersensitivity. Severe hypersensitivity reactions may occur with immune globulin products, including XEMBIFY. In case of hypersensitivity, discontinue infusion immediately and institute appropriate treatment. XEMBIFY contains IgA. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

Please see full Prescribing Information for XEMBIFY® (immune globulin subcutaneous human-klhw) 20%.

Clinical Benefits

An interim pharmacokinetics (PK) analysis on 8 participants was conducted to confirm that a SC dose adjustment factor (DAF) of 1.37 was adequate and safe. The results of this analysis concluded that using an IV to SC dose-adjustment factor of 1.37, was noninferior and bioequivalent as assessed by overall serum exposure to the IV dose of IGIV-C 10% over an equal time interval; additionally, the PK outcomes were similar to those observed in studies of other IGSC products. The authors also noted that the rates of infections and serious bacterial infections were low in patients with PID treated with IGSC-C 20% and comparable with those of other IgG products. Additionally, IGSC-C 20% administered in the home setting was well tolerated in both children and adults.32

The PK of IGSC-C 20% were evaluated in a phase 3, prospective, multicenter, single sequence, open-label study. The primary objective was to determine if IGSC-C 20% was inferior to IGIV-C 10% with respect to the steady-state area under the curve (AUC) of total IgG. Other objectives were to test if IGSC-C 20% replacement therapy had comparable mean steady-state trough levels of total IgG to IGIV-C 10% and to determine the safety of IGSC-C 20%. The study was divided into 5 parts: screening phase, run-in phase, IV phase, SC phase, and an end of study visit. In the run-in phase, participants who were not receiving IGIV-C 10% at 300 to 800 mg/kg per infusion every 3 to 4 weeks for 3 or more months prior to screening were allowed to reach an approximate steady-state prior to PK profiling. The IV phase served as a reference (control) phase; in the SC phase, participants received weekly SC doses of IGSC-C 20% for 24 weeks.32

Based on the PK parameters analyzed, IGSC-C 20% was found to be noninferior and bioequivalent to IGIV-C 10% (geometric least squares mean ratio [SC/IV] for steady state AUC0-7 days ranged from 1.04-1.06).32 Importantly, IGSC-C 20% demonstrated 33% higher trough values than IV administration; higher trough values are associated with lower rates of infection (eg, pneumonia).30,32 During the IV infusion phase, the average IgG concentration rose to 2075 (396) mg/dL and decreased to 913 (192) mg/dL at the end of the 4 weeks. While in the SC phase, all participants had stable IgG levels that were maintained at greater than 580 mg/dL after SC administration. Peak IgG levels after IGSC-C 20% infusion occurred after 76 hours, on average.32

In a population of 49 patients with PID who were administered IGSC-C 20%, results showed a lower rate of any annual infection, serious bacterial infection, number of days treated with antibiotics, number of hospitalizations due to infection, and number of days of work/school missed compared with patients administered IGIV-C 10%. The annual rate of any infections were 2.367 (95% CI 1.601-3.345) in patients treated with IGSC-C 20% compared to 2.750 (95% CI 1.937-3.764) in patients treated with IGIV-C 10%. The rate of serious bacterial infections were 0.049 (95% CI 0.020-0.098) and 0.120 (95% CI 0.051-0.232) in patients treated with IGSC-C 20% and IGIV-C 10%, respectively. The number of days on prophylactic antibiotics were lower in patients administered IGSC-C 20% (27.660 days) compared with patients treated with IGIV-C 10% (34.080 days). The number of hospitalizations were lower in patients treated with IGSC-C 20% (0.049) compared with those administered IGIV-C 10% (0.060). Lastly the number of days of work/school missed were 3.049 (95% CI 1.584-5.221) in patients treated with IGSC-20% and 2.268 (95% CI 1.055-4.174) in patients treated with

IGIV-C 10%.32

Safety

In an analysis of the safety outcomes from the IGSC-C 20% treatment group (n = 49), the majority of the AEs were mild or moderate in severity. A total of 41 patients (83.7%) experienced any grade AE in the SC phase, of which 28.6% were treatment-related AEs. The most common AEs that occurred at a rate of 5% or more in the IGSC-C 20% treatment group included infusion site reactions (infusion site erythema, pain, swelling, bruising, nodule, pruritus, induration, scab, and edema) and systemic reactions (cough and diarrhea) (Table 4).31 Four patients discontinued IGSC-C 20% treatment due to infusion site nodules, infusion site discomfort, skin papules or plaques, and arthralgia or myalgia.32

SUMMARY

PID is associated with significant morbidity and mortality, especially prior to diagnosis, primarily due to recurrent infections, leading to an overall reduction in patient HRQOL.2,17,19 Most patients diagnosed with PID are treated with IgG replacement therapy, which can be administered through IV or SC methods.2 SC administration is useful for patients with a history of AEs from IGIV and poor venous access.23 Additionally, the SC option can be administered at home, which results in improvements in HRQOL compared with IGIV administered at a physician’s office or hospital.23 IGSC-C 20% is a ready-to-use, SC option that has demonstrated safety and tolerability as well as lower rates of annual infection, serious bacterial infection, number of days treated with antibiotics, number of hospitalizations due to infection, and number of days of work/school missed in patients with PID 2 years or older compared with patients treated with IGIV-C 10%.32 IGSC-C 20% displayed higher trough levels than IGIV-C 10% and the higher concentration of IGSC-C 20% allows for patients to use a lower volume than other formulations, which results in shorter infusion times.25,26,32 Taken together, IGSC-C 20% is an efficacious and highly purified therapeutic option for patients with PID that can be self-administered at home.28,32

IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions (continued)

Thrombosis. Thrombosis may occur following treatment with immune globulin products, including XEMBIFY. Thrombosis may occur in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Aseptic meningitis syndrome (AMS). AMS may occur with human immune globulin treatment, including XEMBIFY. Conduct a thorough neurological exam on patients exhibiting signs and symptoms to rule out other causes of meningitis. Discontinuation of treatment has resulted in remission within several days without sequelae.

Renal dysfunction/failure. Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with use of human immune globulin products, especially those containing sucrose. XEMBIFY does not contain sucrose. Ensure patients are not volume-depleted prior to starting infusion. In patients at risk due to preexisting renal insufficiency or predisposition to acute renal failure, assess renal function prior to the initial infusion of XEMBIFY and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation.

Hemolysis. XEMBIFY may contain blood group antibodies that may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for clinical signs and symptoms of hemolysis. If signs and symptoms are present after infusion, perform confirmatory lab testing.

Transfusion-related acute lung injury (TRALI). Noncardiogenic pulmonary edema may occur in patients following treatment with immune globulin products, including XEMBIFY. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of antineutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support.

Transmissible infectious agents. Because XEMBIFY is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD, or CJD have ever been associated with the use of XEMBIFY.

Interference with lab tests. After infusion of XEMBIFY, passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation.

Adverse Reactions

The most common adverse reactions in ≥5% of subjects in the clinical trial were local adverse reactions, including infusion-site erythema (redness), infusion-site pain, infusion-site swelling (puffiness), infusion-site bruising, infusion-site nodule, infusion-site pruritus (itching), infusion-site induration (firmness), infusion-site scab, infusion-site edema, and systemic reactions including cough and diarrhea.

Drug Interactions

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (eg, measles, mumps, rubella, and varicella).

Please see full Prescribing Information for XEMBIFY® (immune globulin subcutaneous human-klhw) 20%.

  1. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497-502. doi:10.1007/s10875-007-9103-1
  2. Diagnostic & Clinical Care Guidelines for Primary Immunodeficiency Diseases. 3rd ed. Immune Deficiency Foundation; 2015.
  3. Joshi AY, Iyer VN, Hagan JB, St Sauver JL, Boyce TG. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc. 2009;84(1):16-22. doi:10.1016/S0025-6196(11)60802-1
  4. Fernández Pérez ER, Hunter M, Katial RK. United States trends in mortality rates for primary immunodeficiency diseases. J Allergy Clin Immunol Pract. 2019;7(3):1045-1048. doi:10.1016/j.jaip.2018.09.030
  5. Seymour B, Miles J, Haeney M. Primary antibody deficiency and diagnostic delay. J Clin Pathol. 2005;58(5):546-547. doi:10.1136/jcp.2004.016204
  6. Immunoglobulin therapy & other medical therapies for antibody deficiencies. IDF website. Accessed March 1, 2020. primaryimmune.org/treatment-information/immunoglobulin-therapy
  7. About primary immunodeficiencies. IDF website. Accessed February 28, 2020. primaryimmune.org/about-primary-immunodeficiencies
  8. Bonilla FA, Khan DA, Ballas ZK, et al; Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the Joint Council of Allergy, Asthma & Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205.e1-e78. doi:10.1016/j.jaci.2015.04.049
  9. McCusker C, Upton J, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol. 2018;14(suppl 2):61. doi:10.1186/s13223-018-0290-5
  10. 2013 IDF national immunoglobin treatment survey. IDF website. Accessed March 10, 2020. primaryimmune.org/sites/default/files/2013_IDF_National_Immunoglobulin_Treatment_Survey.pdf
  11. primary immunodeficiency diseases in America: 2007. IDF website. Published May 1, 2009. Accessed March 23, 2020. https://primaryimmune.org/publication/surveys/primary-immune-deficiency-diseases-america-third-national-survey-patients-2007
  12. Bousfiha AA, Jeddane L, Ailal F, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1-7. doi:10.1007/s10875-012-9751-7
  13. Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007. J Clin Immunol. 2014;34(8):954-961. doi: 10.1007/s10875-014-0102-8
  14. Modell V, Orange JS, Quinn J, Modell F. Global report on primary immunodeficiencies: 2018 update from the Jeffrey Modell Centers Network on disease classification, regional trends, treatment modalities, and physician reported outcomes. Immunol Res. 2018;66(3):367-380. doi:10.1007/s12026-018-8996-5
  15. Abbott JK, Gelfand EW. Common variable immunodeficiency: diagnosis, management, and treatment. Immunol Allergy Clin North Am. 2015;35(4):637-658. doi:10.1016/j.iac.2015.07.009
  16. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650-1657. doi:10.1182/blood-2011-09-377945
  17. Routes J, Costa-Carvalho BT, Grimbacher B, et al. Health-related quality of life and health resource utilization in patients with primary immunodeficiency disease prior to and following 12 months of immunoglobulin G treatment. J Clin Immunol. 2016;36(5):450-461. doi:10.1007/s10875-016-0279-0
  18. Rider NL, Kutac C, Hajjar J, et al. Health-related quality of life in adult patients with common variable immunodeficiency disorders and impact of treatment. J Clin Immunol. 2017;37(5):461-475. doi:10.1007/s10875-017-0404-8
  19. Modell V, Gee B, Lewis DB, et al. Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51(1):61-70. doi:10.1007/s12026-011-8241-y
  20. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354-1360.e4. doi:10.1016/j.jaci.2010.02.040
  21. Menzin J, Sussman M, Munsell M, Zbrozek A. Economic impact of infections among patients with primary immunodeficiency disease receiving IGIV therapy. Clinicoecon Outcomes Res. 2014;6:297-302. doi:10.2147/CEOR.S63200
  22. Chapel HM. Consensus on diagnosis and management of primary antibody deficiencies. BMJ. 1994;308(6928):581-585. doi:10.1136/bmj.308.6928.581
  23. Wasserman RL, Irani A-M, Tracy J, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161(3):518-526. doi:10.1111/j.1365-2249.2010.04195.x
  24. Treatment experiences and preferences among patients with primary immunodeficiency diseases national survey of patients: 2008. IDF website. Published May 6, 2009. Accessed March 23, 2020. https://primaryimmune.org/publication/surveys/treatment-experiences-and-preferences-among-patients-primary-immunodeficiency
  25. Alonso W, Vandeberg P, Lang J, et al. Immune globulin subcutaneous, human 20% solution (Xembify®), a new high concentration immunoglobulin product for subcutaneous administration. Biologicals. 2020;63:34-40. doi:10.1016/j.biologicals.2020.01.004
  26. Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol. 2006;6(4):592-599. doi:10.1016/j.intimp.2005.11.003
  27. Rojavin MA, Hubsch A, Lawo J-P. Quantitative evidence of wear-off effect at the end of the intravenous IgG (IGIV) dosing cycle in primary immunodeficiency. J Clin Immunol. 2016;36(3):210-219. doi:10.1007/s10875-016-0243-z
  28. XEMBIFY® (immune globulin subcutaneous, human—klhw) 20% solution. Prescribing information. Grifols Therapeutics LLC; July 2019. https://www.fda.gov/media/128601/download
  29. Berger M, Murphy E, Riley P, Bergman GE; VIRTUE Trial Investigators. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103(9):856-863. doi:10.1097/SMJ.0b013e3181eba6ea
  30. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21-30. doi:10.1016/j.clim.2010.06.012
  31. BLA approval. FDA website. Published July 3, 2019. Accessed February 29, 2020. fda.gov/media/128602/download
  32. Sleasman JW, Lumry WR, Hussain I, et al. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, phase III study. Immunotherapy. 2019;11(16):1371-1386. doi:10.2217/imt-2019-0159